BPPV, history of gout associated with Ménière's disease

Published Date: 02 Mar 2023

According to a study published online Dec. 26 in the Journal of Clinical Medicine, a history of gout is associated with an increased risk of benign paroxysmal positional vertigo (BPPV) and Ménière's disease.

Read Full News

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

FDA Expansion of Linaclotide for Children 2-5 Years With Functional Constipation Julie Khlevner, MD, AGAF

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Obefazimod Sustains Remission After Dose Reduction in UC Extension Trial Abigail Brooks, MA

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

The HCPFive: Top News for Healthcare Providers from the Week of 05/24 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

6 Gastroenterology Headlines You Missed in May 2026 Abigail Brooks, MA

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Abdominal Pain and Bloating: When to Consider HAE, MCAS, and EGIDs Brian Lacy, MD, PhD

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Todays Updates

8 Pulmonology Headlines You Missed in September 2026

8 Pulmonology Headlines You Missed in September 2026

Congress Passes ACT for ALS Reauthorization, Extending Research Programs Louie Pasculli

The Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 extends federal support for ALS research and expanded access to investigational therapies, with additional provisions addressing clinical trial oversight and regulatory planning.

2026 Rachel Horne Prize Winner Sandra Vukusic, MD, PhD, on Advancing Women's Health in MS Isabella Ciccone, MPH, Sandra Vukusic, MD, PhD

The professor of neurology at the University of Lyon and 2026 Rachel Horne Prize Winner discussed pregnancy counseling, therapeutic inertia, and overlooked women's health issues in multiple sclerosis.

Tips for Clinicians Diagnosing Patients with Diverse Skin Types Mona Shahriari, MD, FAAD, Jennifer Soung, MD

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

AMETHYST: Litifilimab Sustains CLE Gains at 52 Weeks, With Victoria Werth, MD

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

EADV Congress 2026: Day 3 Recap—5 Headlines to Know

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Upadacitinib Tops Nemolizumab on Skin, Itch Targets in Indirect Analysis

Latest News

Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD

Khlevner, MD, discusses the expanded FDA approval of linaclotide for children aged ≥2 years with functional constipation.

Study 108 interim data show 68% of UC patients remained in clinical remission at week 144 after de-escalating from 50 mg to 25 mg obefazimod daily.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and phase 3 data.

Catch up on GI regulatory actions and top headlines from DDW in this May month in review.

Gastroenterologist Brian Lacy, MD, PhD, discusses how to differentiate HAE, MCAS, and eosinophilic GI disorders in patients with unexplained abdominal pain and bloating.

News All Time

FDA Approves Freenome Blood Test for Colorectal Cancer Screening Alex Hillenbrand

FDA approves Freenome's SimpleScreen CRC blood test for colorectal cancer screening in average-risk adults aged ≥45 years.

TL1A Antibody Duvakitug Boosts Clinical Remission in UC, Response in CD Abigail Brooks, MA

Newly published phase 2b RELIEVE UCCD data show strong 14-week results for duvakitug in ulcerative colitis and Crohn disease.

How a Physician With Crohn's Disease Approaches IBD Care Jordan Axelrad, MD, MPH

Jordan E. Axelrad, MD, MPH, on selecting first-line IBD therapy, treat-to-target monitoring, and how living with Crohn's shapes patient care.

ABTECT Part 2 Data: Obefazimod Sustains Remission in UC Remo Panaccione, MD, FRCPC

Remo Panaccione, MD, discusses ABTECT Part 2 data: about 37% of prior non-responders achieved remission, with no new safety signals.

Metabolic Dysfunction May Explain Sugar-Sweetened Beverage–Gastric Cancer Link, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

New findings link sugar-sweetened beverages, but not artificial sweeteners, to increased gastric cancer risk, possibly tied to metabolic dysfunction.

Sugar-Sweetened Beverages Associated With Increased Gastric Cancer Risk, With Andrew Chan, MD, MPH Andrew Chan, MD, MPH

2-decade cohort study of 112,284 participants finds sugar-sweetened beverage intake linked to gastric cancer risk, with no link for artificial sweeteners.

6 Gastroenterology Headlines You Missed in August 2026 Alex Hillenbrand

Gastroenterology in August 2026: RAS inhibitor approval for pancreatic cancer, ABTECT UC data, CRC screening mortality, and GI cancer risk.

TEV '408 Meets Primary Endpoint in Celiac Trial Alex Hillenbrand

The phase 2a study found TEV '408 significantly reduced intestinal damage and inflammation versus placebo at week 8

43% Lower Mortality Seen in Colorectal Screening Participants Johannes Blom, MD, PhD

Karolinska Institute's Johannes Blom, MD, PhD, explains why colorectal cancer screening's real-world mortality benefit has been underestimated.

FDA Approves First-in-Class RAS Inhibitor for Metastatic Pancreatic Cancer Alex Hillenbrand

Daraxonrasib (Rasonque) extended median survival to 13.2 months versus 6.7 months with chemotherapy in a phase 3 trial.

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

Comprehensive Disease Control Starts With Asking, With David T. Rubin, MD

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

The HCPFive: Top News for Healthcare Providers from the Week of 09/06

C Diff Resistance to Bacitracin Reveals Potential Drug Target

C Diff Resistance to Bacitracin Reveals Potential Drug Target

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

SPY003 Meets Primary Endpoint in Phase 2 Trial for Ulcerative Colitis

A Life-Threatening Problem Hidden Within a Hiatal Hernia

Condition resolved after clinicians used a novel oral combination

Cirrhosis-Flagging Tool Stands Out for Steatotic Liver Disease in Primary Care

— SAFE outdid other risk scores in predicting 10-year cirrhosis risk

Recommended News For You

Adjuvant therapy for hepatocellular carcinoma after curative treatment: Several unanswered questions

Colon cancer and exercise: Can physical activity reprogram genes?

Month-Long Wait Times Caused by US Physician Shortage.

Resection for Early Liver Cancer Tied to Improved Survival.

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

UK study evaluates effectiveness of cancer diagnosis pathway for patients with non-specific symptoms

Recommended Articles For You

Understanding Sepsis and Precision-Medicine-Based Immunotherapy: A Pathophysiological Perspective 

Immune Remodeling of the Bone-Marrow Niche: Mechanisms, Clinical Implications, and Emerging Therapies 

Targeting Bone Marrow Immune Niches in Refractory Hematologic Disorders 

Know About Lymphangioma: Symptoms, Causes, and Treatments 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Specialized imaging improves overall prostate cancer survival by identifying benefits of salvage radiotherapy

2.

Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.

3.

In early dementia, SSRIs enhance cognition and major depression.

4.

Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.

5.

Mouse study finds tirzepatide slowed obesity-associated breast cancer growth

1.

Bispecific Antibodies in Hematologic Malignancies: Mechanisms, Clinical Applications, and Future Directions

2.

Teaching Oncologic Emergencies Through Priority-Based Learning

3.

Understanding Protein C Deficiency: Symptoms, Causes, and Treatment

4.

The Future of Cancer Care: Genetics, Support Systems, and Emerging Therapies

5.

Emicizumab in Infants with Severe Hemophilia A: HAVEN 7 Phase 3b Trial Insights

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

How Advances in Cancer Research Are Improving Treatment Options

2.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

4.

Current Scenario of Cancer- Palliative Care to Close the Care Gap

5.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot